Filing Details
- Accession Number:
- 0001209191-22-000647
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-04 16:03:21
- Reporting Period:
- 2022-01-03
- Accepted Time:
- 2022-01-04 16:03:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 651311552 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1655472 | Cindy Tahl | C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131 | General Counsel And Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-03 | 50,000 | $6.55 | 219,006 | No | 4 | M | Direct | |
Common Stock | Disposition | 2022-01-03 | 4,427 | $57.76 | 214,579 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-01-03 | 16,900 | $58.84 | 197,679 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-01-03 | 27,812 | $59.86 | 169,867 | No | 4 | S | Direct | |
Common Stock | Disposition | 2022-01-03 | 861 | $60.31 | 169,006 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2022-01-03 | 50,000 | $0.00 | 50,000 | $6.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
66,643 | 2028-01-16 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 8, 2021.
- Represents the weighted average sale price of the shares sold ranging from $57.26 to $58.18 to per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 5.
- Represents the weighted average sale price of the shares sold ranging from $58.26 to $59.25 per share.
- Represents the weighted average sale price of the shares sold ranging from $59.30 to $60.29 per share.
- Represents the weighted average sale price of the shares sold ranging from $60.30 to $60.33 per share.
- This option is fully vested.